Phase 1 Refractory B-Cell Non-Hodgkin Lymphoma Clinical Trials
15 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC155 enrolled3 locationsNCT07439653
Recruiting
Phase 1
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.100 enrolled15 locationsNCT06189391
Recruiting
Phase 1
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent B Acute Lymphoblastic Leukemia+1 more
University of Michigan Rogel Cancer Center12 enrolled1 locationNCT07532525
Recruiting
Phase 1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
B-cell Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
ADC Therapeutics S.A.200 enrolled42 locationsNCT04970901
Recruiting
Phase 1
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+5 more
Mayo Clinic25 enrolled1 locationNCT04892277
Recruiting
Phase 1
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+3 more
National Cancer Institute (NCI)32 enrolled9 locationsNCT05272384
Recruiting
Phase 1Phase 2
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT07283679
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaHigh Grade B-Cell Non-Hodgkin's Lymphoma+1 more
City of Hope Medical Center15 enrolled1 locationNCT05801913
Recruiting
Phase 1
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
Autolus Limited30 enrolled8 locationsNCT06173518
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Excyte Biopharma Ltd48 enrolled1 locationNCT06565689
Recruiting
Phase 1
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah24 enrolled1 locationNCT06824701
Recruiting
Phase 1Phase 2
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
High-grade B-cell LymphomaNon-Hodgkin LymphomaLymphoma+12 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Non-Hodgkin LymphomaLymphomaLymphoma, Non-Hodgkin+4 more
Caribou Biosciences, Inc.72 enrolled38 locationsNCT04637763
Recruiting
Phase 1
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
Peking University Cancer Hospital & Institute42 enrolled3 locationsNCT06313957